{"nctId":"NCT02623699","briefTitle":"An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)","startDateStruct":{"date":"2016-01-20","type":"ACTUAL"},"conditions":["Amyotrophic Lateral Sclerosis"],"count":176,"armGroups":[{"label":"Part A-SAD: Combined Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Part A-SAD: Cohort 1: Tofersen 10 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Tofersen"]},{"label":"Part A-SAD: Cohort 2: Tofersen 20 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Tofersen"]},{"label":"Part A-SAD: Cohort 3: Tofersen 40 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Tofersen"]},{"label":"Part A-SAD: Cohort 4: Tofersen 60 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Tofersen"]},{"label":"Part B-MAD: Combined Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Part B-MAD: Cohort 5: Tofersen 20 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Tofersen"]},{"label":"Part B-MAD: Cohort 6: Tofersen 40 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Tofersen"]},{"label":"Part B-MAD: Cohort 7: Tofersen 60 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Tofersen"]},{"label":"Part B-MAD: Cohort 8: Tofersen 100 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Tofersen"]},{"label":"Part C-Pivotal: Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Part C-Pivotal: Tofersen 100 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Tofersen"]}],"interventions":[{"name":"Tofersen","otherNames":["BIIB067","QALSODY"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria: Part A and B\n\n* Weakness attributable to ALS and documented SOD1 mutation at Screening Visit 2.\n* A forced vital capacity (FVC) ≥50% of predicted value as adjusted for sex, age, and height (from the sitting position). Participants with stable FVC \\<50% but ≥45%, whose FVC has not declined by more than 5% in the last 6 months may be considered for inclusion, at the discretion of the Investigator.\n* If taking riluzole, participant must be on a stable dose for ≥30 days prior to Day 1 and expected to remain at that dose until the final study visit.\n* Medically able to undergo the study procedures, and to adhere to the visit schedule at the time of study entry, as determined by the Investigator.\n\nKey Exclusion Criteria: Part A and B\n\n* History of or positive test result for human immunodeficiency virus.\n* History of, or positive test result at Screening, for hepatitis C virus antibody.\n* Current hepatitis B infection (defined as positive for hepatitis B surface antigen \\[HBsAg\\] and/or hepatitis B core antibody \\[HBcAb\\]). Participants with immunity to hepatitis B from previous natural infection (defined as negative HBsAg, positive hepatitis B surface antibody immunoglobulin G, and positive HBcAb) or vaccination (defined as positive anti-HBs) are eligible to participate in the study.\n* Treatment with another investigational drug, biological agent, or device within 1 month or 5 half-lives of study agent, whichever is longer. Specifically, no prior treatment with small interfering ribonucleic acid, stem cell therapy, or gene therapy is allowed.\n* Current enrollment in any other interventional study.\n* Current or recent (within 1 month) use, or anticipated need, in the opinion of the Investigator, of copper (II) (diacetyl-bis (N4-methylthiosemicarbazone)) or pyrimethamine.\n* Current or anticipated need, in the opinion of the Investigator, of a diaphragm pacing system (DPS) during the study period.\n\nKey Inclusion Criteria: Part C\n\n* Weakness attributable to ALS and confirmed SOD1 mutation at Screening Visit.\n* If taking riluzole, participant must be on a stable dose for ≥30 days prior to Day 1 and expected to remain at that dose until the final study visit.\n* If taking edaravone, participant must have initiated edaravone ≥60 days (2 treatment cycles) prior to Day 1 and expected to remain at that dose until the final study visit, unless the Investigator determines that edaravone should be discontinued for medical reasons, in which case it may not be restarted during the study. Edaravone may not be administered on dosing days of this study.\n* Medically able to undergo the study procedures and to adhere to the visit schedule at the time of study entry, as determined by the Investigator.\n\nKey Exclusion Criteria: Part C\n\n* History of or positive test result for human immunodeficiency virus.\n* Current hepatitis C infection (defined as positive hepatitis C virus \\[HCV\\] antibody and detectable HCV ribonucleic acid \\[RNA\\]). Participants with positive HCV antibody and undetectable HCV RNA are eligible to participate in the study (United States Centers for Disease Control and Prevention).\n* Current hepatitis B infection (defined as positive for HBsAg and/or anti-HBc). participants with immunity to hepatitis B from previous natural infection (defined as negative HBsAg, positive anti-HBc, and positive anti-HBs) or vaccination (defined as negative HBsAg, negative anti-HBc, and positive anti-HBs) are eligible to participate in the study.\n* Treatment with another investigational drug (including investigational drugs for ALS through compassionate use programs), biological agent, or device within 1 month or 5 half-lives of study agent, whichever is longer. Specifically, no prior treatment with small interfering RNA, stem cell therapy, or gene therapy is allowed.\n* Current enrollment in any other interventional study.\n* Current or recent (within 1 month) use, or anticipated need, in the opinion of the Investigator, of copper (II) (diacetyl-bis(N4-methylthiosemicarbazone)) or pyrimethamine.\n* Current or anticipated need, in the opinion of the Investigator, of a DPS during the study period.\n\nNOTE: Other protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Parts A and B: Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)","description":"An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A SAE is any untoward medical occurrence that at any dose results in death, life-threatening event, requires inpatient hospitalization, significant disability/incapacity or congenital anomaly.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"3","spread":null},{"groupId":"OG004","value":"6","spread":null},{"groupId":"OG005","value":"12","spread":null},{"groupId":"OG006","value":"10","spread":null},{"groupId":"OG007","value":"9","spread":null},{"groupId":"OG008","value":"9","spread":null},{"groupId":"OG009","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"2","spread":null},{"groupId":"OG006","value":"2","spread":null},{"groupId":"OG007","value":"1","spread":null},{"groupId":"OG008","value":"2","spread":null},{"groupId":"OG009","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Parts A and B: Number of Participants With Clinically Significant Laboratory Abnormalities","description":"Clinical laboratory assessments included hematology, chemistry, and urinalysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"2","spread":null},{"groupId":"OG007","value":"1","spread":null},{"groupId":"OG008","value":"0","spread":null},{"groupId":"OG009","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"0","spread":null},{"groupId":"OG009","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"1","spread":null},{"groupId":"OG009","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"1","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"4","spread":null},{"groupId":"OG009","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"1","spread":null},{"groupId":"OG008","value":"3","spread":null},{"groupId":"OG009","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"0","spread":null},{"groupId":"OG009","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"1","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"0","spread":null},{"groupId":"OG009","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"1","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"0","spread":null},{"groupId":"OG009","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Parts A and B: Number of Participants With Clinically Significant Vital Sign Abnormalities","description":"The criteria for clinically significant vital sign abnormalities include: Temperature: \\>38 degree Celsius (°C) or an increase from baseline of ≥1°C; Pulse: \\>120 beats per minute (bpm) or an increase from baseline of \\>20 bpm, \\<50 bpm or a decrease from baseline of \\>20 bpm; Systolic blood pressure (BP): \\>180 mmHg or an increase from baseline of \\>40 mmHg, \\<90 mmHg or a decrease from baseline of \\>30 mmHg; Diastolic BP: \\>105 mmHg or an increase from baseline of \\>30 mmHg, \\<50 mmHg or a decrease from baseline of \\>20 mmHg.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"0","spread":null},{"groupId":"OG009","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Parts A and B: Number of Participants With Clinically Significant Physical Examination Abnormalities","description":"Clinically significant physical examination abnormalities included weight decreased.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"1","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"0","spread":null},{"groupId":"OG009","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Parts A and B: Number of Participants With Clinically Significant Neurological Examination Abnormalities","description":"Clinically significant neurological examination abnormalities included hyporeflexia.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"1","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"0","spread":null},{"groupId":"OG009","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Parts A and B: Number of Participants With Clinically Significant 12-lead Electrocardiograms (ECGs) Abnormalities","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"3","spread":null},{"groupId":"OG006","value":"1","spread":null},{"groupId":"OG007","value":"2","spread":null},{"groupId":"OG008","value":"2","spread":null},{"groupId":"OG009","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"1","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"0","spread":null},{"groupId":"OG009","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Parts A and B: PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.94","spread":null},{"groupId":"OG001","value":"75.06","spread":null},{"groupId":"OG002","value":"202.09","spread":null},{"groupId":"OG003","value":"529.63","spread":null},{"groupId":"OG004","value":"80.75","spread":null},{"groupId":"OG005","value":"229.41","spread":null},{"groupId":"OG006","value":"437.28","spread":null},{"groupId":"OG007","value":"1031.74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG004","value":"112.74","spread":null},{"groupId":"OG005","value":"199.69","spread":null},{"groupId":"OG006","value":"411.00","spread":null},{"groupId":"OG007","value":"1181.83","spread":null}]}]}]},{"type":"PRIMARY","title":"Parts A and B: PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.58","spread":null},{"groupId":"OG001","value":"4.16","spread":null},{"groupId":"OG002","value":"6.00","spread":null},{"groupId":"OG003","value":"2.70","spread":null},{"groupId":"OG004","value":"7.01","spread":null},{"groupId":"OG005","value":"3.68","spread":null},{"groupId":"OG006","value":"2.44","spread":null},{"groupId":"OG007","value":"3.67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG004","value":"3.93","spread":null},{"groupId":"OG005","value":"3.97","spread":null},{"groupId":"OG006","value":"3.12","spread":null},{"groupId":"OG007","value":"3.82","spread":null}]}]}]},{"type":"PRIMARY","title":"Parts A and B: PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve From Time Zero to 24 Hours (AUC0-24h)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"879.86","spread":null},{"groupId":"OG001","value":"1027.18","spread":null},{"groupId":"OG002","value":"2873.77","spread":null},{"groupId":"OG003","value":"5196.11","spread":null},{"groupId":"OG004","value":"1009.85","spread":null},{"groupId":"OG005","value":"2875.13","spread":null},{"groupId":"OG006","value":"4289.16","spread":null},{"groupId":"OG007","value":"11344.47","spread":null}]}]}]},{"type":"PRIMARY","title":"Parts A and B: PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"},{"groupId":"OG001","value":"NA","spread":"NA"},{"groupId":"OG002","value":"NA","spread":"NA"},{"groupId":"OG003","value":"NA","spread":"NA"},{"groupId":"OG004","value":"NA","spread":"NA"},{"groupId":"OG005","value":"NA","spread":"NA"},{"groupId":"OG006","value":"NA","spread":"NA"},{"groupId":"OG007","value":"NA","spread":"NA"}]}]}]},{"type":"PRIMARY","title":"Parts A and B: PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"},{"groupId":"OG001","value":"NA","spread":"NA"},{"groupId":"OG002","value":"NA","spread":"NA"},{"groupId":"OG003","value":"NA","spread":"NA"},{"groupId":"OG004","value":"NA","spread":"NA"},{"groupId":"OG005","value":"NA","spread":"NA"},{"groupId":"OG006","value":"NA","spread":"NA"},{"groupId":"OG007","value":"NA","spread":"NA"}]}]}]},{"type":"PRIMARY","title":"Parts A and B: PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-life (t1/2)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null},{"groupId":"OG003","value":"NA","spread":null},{"groupId":"OG004","value":"NA","spread":null},{"groupId":"OG005","value":"NA","spread":null},{"groupId":"OG006","value":"NA","spread":null},{"groupId":"OG007","value":"NA","spread":null}]}]}]},{"type":"PRIMARY","title":"Parts A and B: PK Parameters of BIIB067 in CSF Levels: Terminal Elimination Half-life (t1/2)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null},{"groupId":"OG003","value":"NA","spread":null},{"groupId":"OG004","value":"NA","spread":null},{"groupId":"OG005","value":"NA","spread":null},{"groupId":"OG006","value":"NA","spread":null},{"groupId":"OG007","value":"NA","spread":null}]}]}]},{"type":"PRIMARY","title":"Part C: Change From Baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Total Score at Week 28","description":"The ALSFRS-R measures 4 functional domains, including respiratory, bulbar function, gross motor skills, and fine motor skills. There are 12 questions, each scored from 0 (no function) to 4 (full function), for a total possible score of 48. Scores decline with disease progression. ALSFRS-R scores calculated at diagnosis can be compared to scores throughout time to determine the speed of progression. Higher scores represent better function, negative change from baseline indicates disease progression.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.1","spread":"1.79"},{"groupId":"OG001","value":"-7.0","spread":"1.42"}]}]}]},{"type":"SECONDARY","title":"Part B: CSF Levels of Total SOD1 Protein Concentration Ratio to Baseline","description":"Total CSF SOD1 protein ratio to baseline was calculated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.97","spread":null},{"groupId":"OG001","value":"0.99","spread":null},{"groupId":"OG002","value":"0.73","spread":null},{"groupId":"OG003","value":"0.79","spread":null},{"groupId":"OG004","value":"0.64","spread":null}]}]}]},{"type":"SECONDARY","title":"Part C: CSF Levels of Total SOD1 Protein Concentration Ratio to Baseline","description":"Total CSF SOD1 protein ratio to baseline was calculated and LS Geometric Mean ratio to baseline was reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.16","spread":null},{"groupId":"OG001","value":"0.71","spread":null}]}]}]},{"type":"SECONDARY","title":"Part C: Neurofilament Light Chain (NfL) Plasma Concentration Ratio to Baseline","description":"NfL is a biomarker whose concentration was assessed in plasma. Plasma NfL ratio to baseline was calculated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.20","spread":null},{"groupId":"OG001","value":"0.40","spread":null}]}]}]},{"type":"SECONDARY","title":"Part C: Change From Baseline in Percent Predicted Slow Vital Capacity (SVC) at Week 28","description":"Vital capacity was measured by means of an SVC test, administered in the upright position.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.20","spread":"4.771"},{"groupId":"OG001","value":"-14.31","spread":"3.557"}]}]}]},{"type":"SECONDARY","title":"Part C: Change From Baseline in Handheld Dynamometry (HHD) Megascore as Measured by the HHD Device at Week 28","description":"Quantitative muscle strength was evaluated using HHD, which tests isometric strength of multiple muscles using standard participant positioning. Sixteen muscle groups were evaluated in both upper and lower extremities. The muscle strength values were normalized to Z scores as (post-baseline measurements - mean)/SD and averaged to provide HHD overall megascore. The overall megascore was created by averaging all eight bilateral measurement Z scores, if no more than 10 (≤ 10) measures are missing. A negative change from baseline indicated decreased muscle strength.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.37","spread":"0.096"},{"groupId":"OG001","value":"-0.34","spread":"0.073"}]}]}]},{"type":"SECONDARY","title":"Part C: Time to Death or Permanent Ventilation","description":"Time to Death or Permanent Ventilation is defined as the time to the earliest occurrence of one of the following events that were adjudicated by an independent committee: Death; Permanent ventilation (≥22 hours of mechanical ventilation \\[invasive or noninvasive\\] per day for ≥21 consecutive days).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Part C: Time to Death","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Part C: Number of Participants Experiencing AEs and SAEs","description":"An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A SAE is any untoward medical occurrence that at any dose results in death, life-threatening event, requires inpatient hospitalization, significant disability/incapacity or congenital anomaly.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":5},"commonTop":["Procedural pain","Headache","Fall","Post lumbar puncture syndrome","Pain in extremity"]}}}